Harmony Biosciences Holdings, Inc. Common Stock (HRMY)
Harmony Biosciences Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with neurological and psychiatric disorders. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, the company specializes in treatments for rare and unmet medical conditions, with a notable focus on narcolepsy and other sleep-related disorders.
Company News
The Developmental and Epileptic Encephalopathies (DEE) market is expected to grow significantly due to approved medications like EPIDIOLEX, rising demand for novel treatments, and the introduction of potential emerging therapies. However, the discontinuation of emerging therapies may impede this growth.
Harmony Biosciences Holdings, Inc. (HRMY) reported better-than-expected earnings and revenue for the second quarter of 2024. However, the company's stock has underperformed the market so far this year, and the earnings outlook is unfavorable, leading to a Zacks Rank #5 (Strong Sell) rating.
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, ...
HRMY earnings call for the period ending March 31, 2024.